News / Announcements
September 29, 2025: FDA approves TREMFYA® for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
June 28, 2025: FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still’s disease (including systemic Juvenile Idiopathic Arthritis (sJIA).
Brunner, H.I., Antón, J., Calvo-Penadés, I., Dimelow, R., Horneff, G., Kamphuis, S., Marino, R., van Maurik, A., Minden, K., Mori, M., Ocran-Appiah, J., Wilkinson, C., Yamasaki, Y., Assudani, D. and for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators (2025), Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open-Label Trial. Arthritis Care Res. Accepted Author Manuscript. https://doi.org/10.1002/acr.25700
Shishov M, Weiss PF, Levy DM, Chang JC, Angeles-Han ST, Ogbu EA, Nanda K, Sherrard TM, Goldmuntz E, Lovell DJ, Rider LG, Brunner HI; of the PRCSG Advisory Council.
Arthritis Care Res (Hoboken). 2024 Dec 9. https://doi.org/10.1002/acr.25482 Epub ahead of print. PMID: 39651592.